Best of ASCO - 2014 Annual Meeting

 

Welcome

Advanced Disease

Head and Neck Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
5-fu continuous pump infusion via superficial temporal artery cannula for high T-staged nasopharyngeal cancinoma: A phase I clinical trial.

Li Xiang

e18011

A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.

Matthew H. Taylor

6016

A phase 1b/2a, multi-center, open-label study to evaluate the safety and efficacy of combination treatment with MEDI0457 (INO-3112) and durvalumab (MEDI4736) in patients with recurrent/metastatic human papilloma virus–associated head and neck squamous cell cancer.

Charu Aggarwal

TPS6093

A phase 2, multicenter study to evaluate the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-145) for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC).

Rom S. Leidner

TPS6096

A phase 2, multicenter, open-label study to evaluate the efficacy and safety of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC).

Julie E. Bauman

TPS6091

A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669.

Ezra E.W. Cohen

TPS6090

A phase I/II trial adding poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel (Carbo-Tax) in patients with head and neck squamous cell carcinoma (HNSCC) Alliance A091101.

Michael J. Jelinek

6031

A phase II prospective study about the efficacy and toxicity of the locally advanced NPC patients treated with CCRT followed with metronomic chemotherapy.

Mei Feng

e18023

A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).

Sean Matthew McBride

6009

A phase II study of lenvatinib in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.

Vatche Tchekmedyian

6022

A pilot trial assessing apatinib in advanced head and neck squamous cell carcinoma that failed in previous standard chemotherapy or chemoradiotherapy.

Hui Wu

e18009

An open-label, non-randomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of the interim safety analysis.

Assuntina Gesualda Sacco

6037

Anti-VEGF treatment to modulate tumor microenvironment (TME) prior to chemotherapy in EBV-positive nasopharyngeal carcinoma (NPC).

Wan Qin Chong

6030

Are women with head and neck cancer undertreated?

Annie Park

LBA6002

Association of a baseline neutrophil-to-lymphocyte ratio (NLR) with progression-free and overall survival in head and neck cancer patients receiving anti-PD-1 therapy.

Corey Christian Foster

6038

Association of immune-related adverse events (irAEs) with improved response, progression-free survival, and overall survival for patients with metastatic head and neck cancer receiving anti-PD-1 therapy.

Corey Christian Foster

6014

CAPTN: A nomogram for predicting survival and guiding therapy for patients with de novo metastatic head and neck squamous cell carcinoma.

Jared R. Robbins

6041

Cetuximab administered once every second week to patients with advanced head and neck cancer: Safety and feasibility of maintenance schedule after first-line chemotherapy.

Raffaele Addeo

e18006

Clinical and immune effects of cetuximab and weekly low dose carboplatin and paclitaxel in head and neck cancer patients with poor performance status.

Marcelo Raul Bonomi

e18005

Comparison between lobaplatin and cisplatin plus 5-fluorouracil combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized phase III clinical trial.

Kuiyuan Liu

6029

Comprehensive analysis of mutation and expression based pathways in head and neck squamous cell carcinoma.

Bhumsuk Keam

e18015

Concomitant chemoradiotherapy using modified TPF (docetaxel, cisplatin and 5-FU) for the patients with advanced sino-nasal squamous cell carcinoma.

Kiyoto Shiga

e18018

COTI-2, a potent orally available small molecule targeting mutant p53, with promising efficacy as monotherapy and combination treatment in preclinical tumor models.

Richard T Ho

6040

ECHO-310: A phase 3, randomized trial of epacadostat + nivolumab + chemo vs EXTREME as first-line treatment of recurrent/metastatic SCCHN.

Ezra E.W. Cohen

TPS6092

Effect of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy on nutritional status in locoregionally advanced nasopharyngeal carcinoma patients: A prospective observational study.

Jingjing Miao

e18002

EORTC 1559-HNCG: A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)—"UPSTREAM".

Rachel Galot

TPS6095

Genetic variants as predictive markers for ototoxicity and nephrotoxicity in patients (pts) with locally advanced head and neck cancer (LAHNC) treated with cisplatin-containing chemoradiotherapy (ccCRT).

Chantal Driessen

e18010

Has the PD-L1 expression in tumor and immune cells the prognostic role in oral cavity squamous cell carcinoma?

Georgy M. Manikhas

e18025

Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in KEYNOTE-040.

Ezra E.W. Cohen

6013

Hyperfractionated reirradiation with cetuximab for recurrent head and neck cancer: The GORTEC 2008-01 multicentric phase II study.

Mathilde Saint-Ghislain

6034

Immunomodulation by the combination of ipilimumab and nivolumab neoadjuvant to (salvage) surgery in advanced or recurrent head and neck carcinoma, IMCISION, an investigator-initiated phase-Ib/II trial (N16IMC, NCT03003637).

Charlotte L. Zuur

e18020

Impact of chronic hepatitis c virus infection in patients with non-oropharyngeal cancers.

Georgios Angelidakis

e18027

Impact of TNM staging, treatment, primary site on survival rates of hypopharyngeal squamous cell carcinoma: A population-based analysis.

Gehad Mohamed Tawfik

e18028

Induction capecitabine and cisplatin followed by hypofractionated radiotherapy in locally advanced head and neck cancer.

Quratul Ain Hashmi

e18012

Induction chemotherapy (IC) using cisplatin and 5-fluorouracil followed by bioradiotherapy (BRT) in stage IVb squamous cell carcinoma of oropharynx and oral cavity: Retrospective data analysis.

Igor Djan

e18029

Induction chemotherapy with paclitaxel liposome, nedaplatin, and fluorouracil in patients with locally advanced nasopharyngeal carcinoma: A phase II study.

Jing Yan

e18024

Investigating the feasibility of targeted next-generation sequencing to guide the treatment of head and neck squamous cell carcinoma.

Bhumsuk Keam

e18017

Long-term outcomes after induction chemotherapy with docetaxel, cisplatin and 5-FU (TPF) followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal cancer.

Sang-Hee Cho

e18008

Multicenter phase II trial of palbociclib, a selective cyclin dependent kinase (CDK) 4/6 inhibitor, and cetuximab in platinum-resistant HPV unrelated (-) recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC).

Douglas Adkins

6008

Nivolumab (nivo) vs investigator’s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.

Nabil F. Saba

6028

Outcomes of concurrent radiation with cisplatin versus cetuximab in locally-advanced head and neck squamous cell carcinoma (LAHNSCC).

Ly Viet Do

e18007

Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study.

Jean-Pascal H. Machiels

TPS6094

Phase I/II trial of pembrolizumab(P) and vorinostat(V) in recurrent metastatic head and neck squamous cell carcinomas (HN) and salivary gland cancer (SGC).

Cristina P. Rodriguez

6025

Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma.

Trisha Michel Wise-Draper

6017

Phase II trial of apatinib in patients with recurrent and/or metastatic adenoid cystic carcinoma of the head and neck: Updated analysis.

Guopei Zhu

6026

PMMC deltopectoral (DP) Composite sandwich flap: A innovative locoregional solution for huge complex defects after head and neck cancer surgery.

Jeetendra Paryani

e18003

Possible CDK4/6 inhibitor use in betel-nuts related head and neck squamous cell carcinoma(HNSCC).

Jo-Pai Chen

e18030

Profiling metastatic lesions from a pembro-refractory patient to reveal distinct genomic instabilities and non-uniform response to drug combinations, ex vivo.

Chukwuemeka Ikpeazu

e18021

Radiotherapy with concurrent Avelumab and Cetuximab as primary treatment in patients with locally advanced squamous cell carcinoma of the head and neck: A phase-IB feasibility trial in patients unfit for cisplatin (NCT02938273).

Joris B. W. Elbers

e18019

Randomised phase II study with cetuximab in combination with 5-FU and cisplatin or carboplatin versus cetuximab in combination with paclitaxel and carboplatin for treatment of patients with relapsed or metastatic squamous cell carcinoma of the head and neck (CETMET trial).

Signe Friesland

6032

Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck.

Khalil Saleh

6015

RM-1929 photo-immunotherapy in patients with recurrent head and neck cancer: Results of a multicenter phase 2a open-label clinical trial.

Ann M. Gillenwater

6039

Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232).

Kevin J. Harrington

6036

Saline alone vs saline plus mannitol hydration for the prevention of acute cisplatin nephrotoxicity: A randomized trial.

Bradley Beeler

6035

Speech efficacy, safety and factors affecting lifetime of voice prostheses in patients with laryngeal cancer: A systematic review and network meta-analysis of randomized controlled trials.

Gehad Mohamed Tawfik

e18031

Stereotactic body radiotherapy to extend the clinical benefit of PD-1 inhibitors in recurrent/metastatic nasopharyngeal carcinoma.

Yu Chen

e18013

Survival with nivolumab therapy in recurrent/advanced squamous cell head and neck carcinoma. A single center experience.

Ana Laura Ortega Granados

e18032

Toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin ineligible head and neck cancer patients.

Vijai Simha

e18022

Triple combination treatment of cetuximab, chemotherapy, and anti-PD1 check-point inhibitor for recurrent and/or metastatic head and neck squamous cell carcinoma: A single institute experience.

Ying-Chu Lin

e18001